Abstract
Epstein-Barr virus (EBV) is a latent herpesvirus that is associated with a number of tumors. EBV-infected cells show three patterns of latency ranging from type 1, where only one EBV-encoded antigen is expressed, to type 3, where all nine latent cycle proteins encoded by EBV are expressed. Malignancies exhibiting the type 3 latency pettern are highly immunogenic and occur only in immunocompromised patients. It has recently been shown that adoptive immunotherepy with EBV-specific cytotoxic T lymphocytes is an effective therapy for such tumors. Immunotherapy strategies and approaches to increase tumor immunogenicity are now being evaluated in tumors expressing type 2 latency.
Original language | English (US) |
---|---|
Pages (from-to) | 24-30 |
Number of pages | 7 |
Journal | Molecular Medicine Today |
Volume | 3 |
Issue number | 1 |
DOIs | |
State | Published - 1997 |
ASJC Scopus subject areas
- Molecular Medicine
- Genetics